Drug repurposing in malignant pleural mesothelioma: a breath of fresh air?

European Respiratory Review 2018 March [Print 2018 March 31] Link] Boyer A, Pasquier E, Tomasini P, Ciccolini J, Greillier L, Andre N, Barlesi F, Mascaux C Abstract Drug repurposing is the use of known drugs for new indications. Malignant pleural mesothelioma (MPM) is a rare cancer with a poor prognosis. So far, few treatments have…

Read More

Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605) Reduces Asbestos-Induced Cytotoxicity in an Nrf2-Dependent and -Independent Manner

Antioxidents 2018 March [Link] Pietrofesa RA Abstract Asbestos exposure triggers inflammatory processes associated with oxidative stress and tissue damage linked to malignancy. LGM2605 is the synthetic lignan secoisolariciresinol diglucoside (SDG) with free radical scavenging, antioxidant, and anti-inflammatory properties in diverse inflammatory cell and mouse models, including exposure to asbestos fibers. Nuclear factor-E2 related factor 2…

Read More

Breath analysis by gas chromatography-mass spectrometry and electronic nose to screen for pleural mesothelioma: a cross-sectional case-control study

Oncotarget 2017 September [Link] Lamote K, et. al Abstract RATIONALE: Malignant pleural mesothelioma (MPM) is mainly caused by previous exposure to asbestos fibers and has a poor prognosis. Due to a long latency period between exposure and diagnosis, MPM incidence is expected to peak between 2020-2025. Screening of asbestos-exposed individuals is believed to improve early…

Read More

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial

Journal of Clinical Oncology 2017 September 11 [Epub ahead of print] [Link] Grosso F, Steele N, Novello S, Nowak AK, Popat S, Greillier L, John T, Leighl NB, Reck M, Taylor P, Planchard D, Sørensen JB, Socinski MA, von Wangenheim U, Loembé AB, Barrueco J, Morsli N, Scagliotti G Abstract Purpose LUME-Meso is a phase…

Read More

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

The Lancet.Oncology 2017 July 17 [Epub ahead of print] [Link] Maio M, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, Taylor P, Grosso F, Antonia SJ, Nowak AK, Taboada M, Puglisi M, Stockman PK, Kindler HL Abstract BACKGROUND: New therapeutic strategies for malignant mesothelioma are…

Read More

Giant primary malignant mesothelioma of the liver: A case report

International Journal of Surgery Case Reports 2016 November [Epub ahead of print] [Link] Haji Ali R, Khalife M, El Nounou G, Zuhri Yafi R, Nassar H, Aidibe Z, Raad R, Abou Eid R, Faraj W Abstract INTRODUCTION: Malignant mesothelioma is a rare neoplasm of mesothelial cells arising most frequently in the pleura or peritoneum and…

Read More

Metformin and survival of people with type 2 diabetes and pleural mesothelioma: A population-based retrospective cohort study

Lung Cancer (Amsterdam, Netherlands) 2016 September [Epub 2016 July 20] [Link] Wu H, Walker J, Damhuis RA, Brewster DH, Wild SH; Scottish Diabetes Research Network Epidemiology Group Abstract OBJECTIVES: This study aimed to investigate the effect of metformin on survival of people with type 2 diabetes and pleural mesothelioma. MATERIALS AND METHODS: We conducted a…

Read More